E-Newsletter - December 2019


The American Society of Hematology (ASH) is the world's largest professional society serving both clinicians and scientists who are working to conquer blood diseases. ASH represents more than 17,000 members from nearly 100 countries. The Alliance for Clinical Trials in Oncology and Alliance Foundation Trials, LLC presented an array of novel data from many of its hematology studies during the 61st ASH Annual Meeting and Exposition December 7-10 in Orlando, FL. Many of these data will help change the delivery of hematologic cancer care or help elucidate the underlying cause and effect relationships seen in this field.

Here's a snapshot of studies that were presented.

Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVD) Improves Over Time in Patients (pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): GRIFFEN Study Update (AFT-29)
Lead author: Peter Voorhees, MD
Abstract #: 691

Alliance A041701 - A Randomized Phase 2/3 Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
Lead author: Geoffrey Uy, MD
Abstract #: 1366

Alliance A041702
Alliance A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (≥ 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)
Lead author: Jennifer Woyach, MD
Abstract #: 1751

CALGB (Alliance) 20202, CALGB 8461, CALGB 9665
Personalized Oncology in Acute Myeloid Leukemia (AML): Validation of the Prognostic Value of the Knowledge Bank Approach in Patients (Pts) Treated on Cancer and Leukemia Group B/Alliance Protocols
Lead author: Marius Bill, MD, PhD
Abstract #: 182

CALGB (Alliance) 20202, CALGB 8461, CALGB 9665
The 2017 European LeukemiaNet Genetic Risk Classification performs poorly in elderly Acute Myeloid Leukemia (AML) patients and should be refined to enable identification of patients requiring additional or alternative treatment (Alliance)
Lead author: Ann-Kathrin Eisfeld, MD
Abstract #: 2681

CALGB (Alliance) 20202, CALGB 8461, CALGB 9665
Next-Generation RNA Sequencing-Based Analysis Identifies a Novel Set of Prognostic MicroRNAs (miRs) in Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) (Alliance)
Lead author: Dimitrios Papaioannou, MD
Abstract #: 2694

CALGB (Alliance) 20202, CALGB 8461, CALGB 9665
Distinct Gene Expression Profiles and Mutations Are Associated with Disease Relapse after Achievement of Complete Remission (CR) in Adult Patients younger than 60 years with de novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) (Alliance)
Lead author: Christopher Walker, MD
Abstract #: 1247



For other articles in this issue of the Alliance E-News newsletter, see below.